2048 Ventures

2048 Ventures Research Investment Thesis & Core Philosophy 2048 Ventures is a thesis-driven early-stage venture capital firm based in NYC and Boston that invests exclusively in visionary founders building transformative technologies in their four core focus areas: Vertical AI, Deep Tech, Healthcare, and Biotech. The firm believes that the next generation of great companies will be built on defensible data moats and novel technological breakthroughs that solve fundamental problems. Their investment philosophy emphasizes long-term value creation and partnership with founders from day zero, with a proven NPS score of 100 from their portfolio founders. The firm is not a traditional early-stage investor. Rather than diversifying broadly, 2048 Ventures maintains strict thesis discipline, concentrating capital in deep technology areas where the founders have conviction. Their approach combines rapid decision-making with hands-on operational support, positioning themselves as "the least annoying and most helpful investor on your cap table." Fund Structure & Strategy 2048 Ventures Fund III closed in January 2026 with $82 million in capital (oversubscribed). This is the firm's largest fund to date, representing significant growth from their earlier funds. Fund III is currently in the active deployment phase with explicit focus on Pre-Seed and Seed stage investments across their four core verticals. The firm operates a straightforward investment model with direct startup investments at Pre-Seed and Seed stages, check sizes of $500K - $3M, and a special Pre-Seed Fast Track program enabling funding in as little as 10 business days for $500K-$1.5M rounds. Stage Focus & Check Size 2048 Ventures explicitly targets the earliest stages of company development, with particular strength in Pre-Seed and Seed rounds. Primary stages are Pre-Seed and Seed, with selective Series A follow-ons. Check sizes range from $500K-$1.5M for Pre-Seed (with 10-day funding guarantee) to $500K-$3M for Seed, with target ownership of 15-20% at Seed stage. The firm prides itself on rapid decision-making: from first meeting to commitment to lead a round takes just 10-15 business days, which is particularly distinctive at the Pre-Seed stage where capital constraints often slow founder growth. Lead Tendency 2048 Ventures leads rounds. This is a defining characteristic explicitly stated across their marketing materials. They do not participate passively but actively lead both Pre-Seed and Seed rounds. Once committed, they use their network to help founders pull together the remainder of the round, viewing their role as actively shaping company formation and early momentum. Recent Activity & Fund Status Fund III Status: Actively deploying. Closed January 29, 2026, with $82M raised in an oversubscribed round. Recent Investments (Last 12 Months): January 2026: Nionyx Bio - AAV-based gene therapies for kidney genetic diseases (Biotech) July 2025: Kascaid - Interstitial fluid biosensor for immune monitoring (Health/Deep Tech) June 2025: Nimbus Health - Pulmonology platform (Health/Deep Tech) May 2025: Aslan Protects - Proactive intelligence for public safety (Deep Tech) April 2025: Rondah AI - Agentic workforce for patient engagement (Vertical AI) November 2024: Tetsuwan Scientific - Autonomous AI scientists (Vertical AI) October 2024: Psyrin - Objective biomarkers for mental health (Health/Biotech) October 2024: Aerodome acquisition by Flock Safety (successful exit) Portfolio Highlights & Track Record The 2048 Ventures portfolio spans approximately 80+ companies since inception in 2019, demonstrating clear thesis focus across Vertical AI, Deep Tech, Healthcare, and Biotech verticals. Notable Exits: Aerodome acquired by Flock Safety (first responder drone platform) GlossGenius: $28M Series C (beauty industry SaaS) Soona: $35M Series B (e-commerce content platform) Vitally: $30M Series B (customer success platform) Active Portfolio by Vertical AI: Rondah AI, Tetsuwan Scientific, Pageport, Persist AI, nextmv Active Portfolio by Deep Tech: Aerodome, Tangram Vision, Wareclouds, Enurgen, Adaptis, H2Ok Innovations Active Portfolio by Healthcare/Biotech: Nionyx Bio, Kascaid, Nimbus Health, FemTherapeutics, TwoStep Therapeutics, Century Health, Psyrin, Neobe Team & Leadership 2048 Ventures has assembled a deep team combining serial entrepreneurship with domain expertise across focus areas. Investment Partners: Alex Iskold - Founder and Partner 5x founder with software engineering background. Former Managing Director of Techstars NYC (5 years). Founded and sold Info Lab to IBM, GetGlue (backed by USV, RRE, Time Warner), and Chief Architect of DataSynapse (acquired by TIBCO). VC in Residence at Harvard Business School. B.S. Math from Lehigh University, M.S. Computer Science from NYU. Zann Ali - Partner Prior: Putnam Investments and Fidelity Investments (4 years). Pre-seed investor with MIT Dorm Room Fund (20+ companies). Teaching team for MIT's Entrepreneurial Finance course. B.S. Statistics & Finance from Babson College, MBA from MIT Sloan. Julie Wolf, PhD - Partner Investor in 50+ startups. Prior Chief Science Officer at SOSV's IndieBio New York. Scientific research and biotech entrepreneurship background. Ph.D. Microbiology, Immunology, and Cancer Biology from University of Minnesota. Daniella Cohen - Principal Prior: Managing Partner at Rough Draft Ventures. Summer associate at Techstars NYC. Worked at The Clear Cut (DTC diamond startup) as Head of Content. Early employee at Facebook. B.A. Neuroscience from Princeton University. Sandra Pérez Baos, PhD - Senior Associate Founding leadership at Nucleate New York. 10+ years in translational immunology and molecular biology research. Ph.D. Molecular Biosciences from Autonomous University of Madrid. Edward Jin - Associate Pre-seed investor with Crescent Fund and Dorm Room Fund. Research experience at Spero Ventures. Product roles at Fileread and Armada. B.S. Mathematics–Computer Science from UC San Diego. Lilly Iskold - Analyst Research experience at Humane Genomics and New York Genome Center. B.A. Biology from Brandeis University. Alice Iskold - Analyst Interned at PathSpot health tech startup. Research experience at New York Genome Center. B.A. Biology from Brandeis University. Justine Marchand - VP of Finance & Operations Led launch and operations of Techstars Montréal AI accelerator (4 cohorts). Master's Degree in Innovation & Entrepreneurship from INSEEC School of Business and Economics. Colette Jumbert - Operations Associate Research projects at McGill Desautels Faculty of Management. Product roles at Dōpu (specialty coffee) and Digitad (digital marketing). B.A. Economics and International Development from McGill University. Decision Process & Engagement Model Decision Making: Partnership model with multiple investment partners. Collective decisions with partner leads on specific verticals (Julie Wolf leads Healthcare/Biotech, Alex and Zann lead Vertical AI/Deep Tech). Deal Flow: Direct pitch process (no warm introduction required). Founders can pitch anytime via website. The firm reviews 100% of pitches received. Warm Intro Required: No. Explicitly states "You do not need a warm introduction to get in touch." Typical Involvement: Active board seat or observer participation at Seed stage and above. Operational mentorship, network introductions, and strategic advice. Occasional involvement in later-stage follow-on rounds. Decision Timeline: Pre-Seed and Seed: 10-15 business days from first meeting to commitment. Fast Track: as little as 10 business days for $500K-$1.5M rounds. Geographic Focus Headquarters: NYC and Boston (dual operating cities) Primary Investment Regions: New York City, Boston, Broader Northeast US Portfolio Distribution: Concentrated in NYC and Boston, with secondary presence in Denver, Bay Area, and other US locations. Sector Focus & Classification 2048 Ventures maintains strict thesis discipline across four core verticals with all investments aligned to at least one area. Core Verticals: Vertical AI - AI applications in specific industries with defensible data moats (agentic systems, industry-specific AI, optimization platforms) Deep Tech - Infrastructure, robotics, novel technical breakthroughs (robotics/automation, logistics, public safety, advanced manufacturing) Healthcare - Digital health platforms, diagnostics, health tech services (patient engagement, clinical data, health monitoring) Biotech - Life sciences, therapeutics, synthetic biology, genomic medicine (gene therapies, peptide platforms, bacterial engineering, immunotherapy) Other Sectors (Limited/Historical): E-commerce & Marketplaces (Soona, GlossGenius, Ettos), Consumer & Media (Combo, Wirestock, Kanary), Web3/Blockchain (Carma, Valist), Fintech (Frate, Walnut, Painworth), Logistics (Wareclouds, Ware). Anti-Thesis: Companies outside four core verticals. Pure consumer applications without technical defensibility. Late-stage companies (Series C+) except strategic follow-ons. Companies lacking founder vision and conviction. Unique Positioning & Competitive Advantages Thesis Discipline: Strict focus on four core verticals ensures deep conviction and expertise Speed: 10-15 business day decision timeline and Pre-Seed Fast Track (10 days) is faster than most early-stage firms Founder Affinity: Three of four investment partners are serial founders. NPS score of 100 from portfolio founders Scientific Expertise: Julie Wolf's biotech background and team's science depth enables credible Deep Tech/Biotech evaluation Recent Fund Growth: $82M Fund III (January 2026) represents 2-3x growth, indicating strong LP confidence Dual City Model: NYC and Boston bases provide geographic coverage across two major ecosystems Operational Team: Justine Marchand's accelerator experience brings operational rigor unusual for early-stage firms Founder Preferences & Selectivity 2048 Ventures targets visionary founders with clear conviction about future technology direction. They seek teams with deep domain expertise (founder-market fit), mission-driven focus on fundamental problems, technical founders with product sensibilities, and scientific minds for biotech. They explicitly state investment interest in "mission-driven team, with strong founder-market fit and a vision for what the future should look like," seeking founders willing to build long-term value. Notable Co-Investors & Syndicate Partners Based on portfolio investments and mentions: Founder Collective, First Row Partners, SOSV, USV (Union Square Ventures), RRE Ventures, Bain Capital Ventures, Next47, Capital One Ventures, Techstars, Rough Draft Ventures. These reflect the firm's positioning in premier early-stage networks. Investment Philosophy & Values Core Values: Partner with founders from day zero Earn founder trust through transparency and reliability Become "the least annoying and most helpful investor on your cap table" Never ghost founders or waste their time Deep conviction in core thesis areas Long-term value creation over quick exits Founder Support Model: Active network access post-investment Introductions for customer acquisition and hiring Strategic advice on fundraising and product development Portfolio company collaboration and ecosystem building Potential board seat or observer participation Historical Performance & Track Record Since inception in 2019 (5+ years of operation): Approximately 80+ portfolio companies backed Multiple successful exits including Aerodome acquisition by Flock Safety Notable growth-stage achievements: GlossGenius ($28M Series C), Soona ($35M Series B), Vitally ($30M Series B) Fund progression: Fund I → Fund II → Fund III ($82M, January 2026) Consistent early-stage deployment with thesis discipline maintained across all funds Summary 2048 Ventures represents a thesis-driven, founder-friendly early-stage venture firm with deep conviction in Vertical AI, Deep Tech, Healthcare, and Biotech. Their $82M Fund III (closed January 2026) provides ample capital for their $500K-$3M check size strategy. The firm's competitive advantages include rapid decision-making (10-15 business days), founder-first values (NPS 100), scientific expertise (Julie Wolf's biotech background), and operational rigor. With dual bases in NYC and Boston, strong historical track record, and commitment to leading Pre-Seed and Seed rounds, 2048 Ventures is a compelling early-stage partner for founders aligned with their core thesis areas and values.